The Food and Drug Administration (FDA) on Friday expanded its emergency use authorization (EUA) of Eli Lilly and Co’s dual-antibody therapy for mild to moderate COVID-19 to all children, including newborns. The treatment consists of bamlanivimab and etesevimab—two monoclonal antibodies that are administered by intravenous infusion. The two monoclonal antibodies are directed against the spike protein of SARS-CoV-2,…
FDA Authorizes Eli Lilly’s COVID-19 Antibody Therapy for Children
The Food and Drug Administration (FDA) on Friday expanded its emergency use authorization (EUA) of Eli Lilly and Co’s dual-antibody therapy for mild to moderate COVID-19 to all children, including newborns. The treatment consists of bamlanivimab and etesevimab—two monoclonal antibodies that are administered by intravenous infusion. The two monoclonal antibodies are directed against the spike protein of SARS-CoV-2,…
FDA Grants Eli Lilly’s Experimental COVID-19 Antibody-Drug Emergency Use Authorization
Eli Lilly’s COVID-19 antibody-drug has been granted emergency use authorization by the Food and Drug Administration (FDA), widening access to a therapy that has shown improvement in treating patients with mild to moderate cases of the CCP virus. Data from a late-stage trial last month showed that Eli Lilly’s combination therapy of two antibodies, bamlanivimab and…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`